FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 8, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POTOMAC study Source RELATED ARTICLESMORE FROM AUTHOR Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 Blood Test May Help Identify Which Colorectal Cancer Patients with Liver Metastases Are Most Likely to Benefit from Chemotherapy After Surgery MOST POPULAR ΚΑΡΚΙΝΟΣ ΣΤΟΜΑΧΟΥ February 7, 2019 NICE recommends pembrolizumab for 1,600 more people with breast cancer November 14, 2022 Survivor Story: Erin June 4, 2021 High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent... June 8, 2022 Load more HOT NEWS Blood Test Accurately Detects Early-Stage Pancreatic Cancer Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical... ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular... Metastatic Colorectal Cancer May Spread Early in the Disease, Study Finds
